Our Pipeline

Advancing non-invasive diagnostics through innovative biomarker research.

Illustration of Double-Strand LLC’s research pipeline

Our Research Pipeline

PRAD (Prostate Adenocarcinoma) Project

Our lead program focuses on developing a non-invasive diagnostic test for prostate adenocarcinoma using cell-free nucleic acid biomarkers. This project aims to improve early detection and monitoring of prostate cancer, offering a less invasive alternative to traditional biopsies.

  • Intellectual Property: Provisional patent application filed for novel cfNA biomarkers.
  • Status: Under active research investigation, with ongoing studies to validate biomarker sensitivity and specificity.

Lung and Colon Cancer Projects

Our next phase of research targets non-invasive diagnostic tests for lung and colon cancer, leveraging cell-free nucleic acids to detect early-stage disease and monitor treatment response. These projects are in the early discovery phase, building on our expertise in biomarker identification.

  • Intellectual Property: Pre-patent research in progress.
  • Status: Early-stage research to identify candidate biomarkers.
Inquire About Partnerships